Phosphodiesterase 3 Inhibitor [EPC]

Known as: Phosphodiesterase 3 Inhibitor, Phosphodiesterase III Inhibitor 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1996-2014
01219962014

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
OBJECTIVE To assess the efficacy and safety of cilostazol on the progression and regression of symptomatic intracranial artery… (More)
  • figure 4
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2014
2014
BACKGROUND Hypotension and bradycardia are known to occur frequently in carotid artery stenting (CAS), which may lead to… (More)
Is this relevant?
2014
2014
OBJECTIVE To investigate whether bladder dysfunction after bladder outlet obstruction (BOO) could be altered by treatment with… (More)
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Review
2010
Review
2010
MOTS CLÉS Association d’antiagrégants plaquettaires ; Maladie thrombotique More than 22 million Americans are estimated to take… (More)
  • table 1
Is this relevant?
2008
2008
BACKGROUND Cilostazol, a phosphodiesterase 3 inhibitor, is an antiplatelet drug that is widely used for preventing cardiovascular… (More)
Is this relevant?
1999
1999
The effect of topical administration of phosphodiesterase (PDE) 3 inhibitors on the airway is not clear. In order to examine the… (More)
Is this relevant?
1996
1996
1. This study was designed to investigate the role of rat phosphodiesterase 3 (RPDE3) in regulation of liver metabolism in sepsis… (More)
Is this relevant?